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To elucidate the spread of Borna disease virus (BDV) in Asian countries, we surveyed
48 normal horses in Bangladesh and their 26 caretakers for the BDV antibody by electro-
chemiluminescence immunoassay.  Eleven horses (23%) were found positive.  None of
the 5 horses at the age of < 1 year was positive.  Seven of 23 horses (30%) at the age of
1 year were positive, as well as 4 of 16 horses (25%) at the age of ≥ 3 years.  The geometric
average of the ECLIA titer of the antibody positive horses at the age of 1 year, 3041,
was significantly lower than that found at the age of ≥ 3 years, 6887, by the Mann-
Whitney test (P = 0.012).  Sexual preference in the prevalence of anti-BDV was not
evident.  None of the 26 male horse caretakers between the ages of 12 to 54 years was
positive, including those who were taking care of the antibody positive horses.  Total
RNA extracted from the peripheral blood nucleated cells was tested by polymerase
chain reaction coupled with reverse transcription capable of detecting 200 molecules of
BDV p40 RNA per reaction.  None of the 11 seropositive horses and the 5 randomly
selected seronegative horses was positive.  The results showed that BDV is penetrating
the Bangladeshi labor horse population with similar levels reported in Germany, Iran
and Japan, although the viral genome in the blood was not detected.
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Recently much attention has been paid to the
Borna disease virus (BDV) because of the de-
tection of BDV-positive patients with neuro-
psychiatric disorders suggesting a possible link
between BDV and human disease (Lipkin et al.,
1995; Bechter et al., 1996).  The wide host
range of BDV is consistent with the possibility
of zoonotic spread from animals (Waelchli et al.,
1985; Ludwig et al., 1988; Bode et al., 1994;
Lundgren et al., 1995; Bode and Ludwig, 1997).
The current list of natural hosts for BDV in-
cludes horses, sheep, cattle, cats and ostriches
(Waelchli et al., 1985; Ludwig et al., 1988; Bode
et al, 1994; Weisman et al., 1994; Lundgren et al.,
1995).  Seroepidemiological studies suggested
that animal care workers had a higher preva-
lence of anti-BDV antibody (Weisman et al.,
1994; Takahashi et al., 1997).  Bechter et al.
(1992, 1996) reported neuropsychiatric patients
with anti-BDV antibody who had histories of
working in BDV-positive animal farms.  Some
researchers even tried to correlate human men-
tal disorder cases with cats in the household
(Torrey et al., 1995).
Still, little is known about the natural reser-
voir of BDV for human infection.  The neurol-
ogic manifestations of BDV infection in horses
is similar to the neuropsychiatric disorders in
human (Bode and Ludwig, 1997).  Prehistoric
“sad horse disease” or “head disease” has now
been proven to be an immune mediated enceph-
alitis caused by BDV.  The horse was the first
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animal described as a natural host of BDV
(Ludwig et al., 1988).  In the early days, it was
generally believed that the Borna disease in the
horse was endemic only in southern Germany
and Switzerland (Rott and Becht, 1995).  How-
ever, the presence of horses seropositive for
anti-BDV antibody in recent studies from the
United States, Japan, Iran, Austria and Sweden
changed the view that BDV is more widespread
than previously thought (Kao et al., 1993;
Nakamura et al., 1995; Bahmani et al., 1996;
Weissenbock et al., 1998; Berg et al., 1999).  As
far as we know, there has been no report on
BDV in the horses of southeast Asia.  In the typ-
ical southeast Asian situation, horses are usual-
ly reared in the same house together with hu-
mans who then have a greater chance of threat
from any virus with zoonotic properties.  Here
we report BDV prevalence by testing the anti-
body and the genome in normal Bangladeshi
horses and their caretakers living in the same
house.
Materials and Methods
Blood
One milliliter of blood with EDTA as an anti-
coagulant was collected from 48 normal horses
and 26 horse-caretakers in Bangladesh.  The
whole blood was preserved at –20˚C until use.
After thawing the frozen blood, the fluid por-
tion separated by centrifugation at 3000 rpm for
5 min at room temperature was used for detec-
tion of anti-BDV antibody by  electrochemilu-
minescence immunoassay (ECLIA) (Yamaguchi
et al., 1999).  The nucleated cells in the precipi-
tate were used for the detection of BDV RNA
by reverse transcription-polymerase chain reac-
tion (RT-PCR).  This method is not ideal but
useful in testing for antibodies and viral ge-
nomes in field conditions where routine experi-
mental equipment, such as a centrifuge, are un-
available (Kawase et al., 1992).  During the pe-
riod of thawing the frozen whole blood, red
cells will burst but nucleated cells keep their
cytoplasmic membrane.
Antibody Titration
The antibody was titrated by ECLIA.  Briefly,
20 µL of serum at 1/10 dilution was preincu-
bated overnight with 200 µL of normal chicken
serum with or without 1 mg each of recombi-
nant BDV peptides, rp24 and/or rp40.  Micro-
beads (magnetic polystyrene beads coated with
a polyurethane layer, No. 140.03, Dynal As,
Oslo, Norway) coated with the peptides were
incubated at 30˚C for 9 min with the preincu-
bated serum.  After washing, the beads were
incubated with 200 µL of 200 ng/mL anti-horse
or anti-human immunoglobulin G (Sigma, St.
Louis, MO) coupled with Ru(bpy)32+ [rutheni-
um (II) tris (bipyridyl)-N-hydroxysuccinimide
ester (IGEN Int. Inc., Gaithersburg, MD)].  At
every washing step, the well was washed with
0.05-mol/L Tris-HCl, pH 8.0, 0.01% Tween-20
and 10% normal chicken serum 3 times.  The
ECLIA count was computed automatically by
an automatic ECLIA analyzer (Picolumi 8220,
Sanko Jyunyaku, Tokyo, Japan) based on opti-
cal density at 620 nm.  A sample was consider-
ed positive when the ECLIA count was higher
than the mean of control blood samples plus 3
SDs, and > 50% of the count was competed out
by the recombinant peptide antigen as previous-
ly described (Yamaguchi et al., 1999).  This
criterion was selected since some sera showed
non-specific reactivity which could not com-
pete with the purified antigen (Yamaguchi et
al., 1999).
Extraction of RNA
RNA was extracted by a guanidium thiocyanate
extraction method (Chomczynski and Sacchi,
1987) with minor modifications.  Briefly, the
cellular fraction obtained from 1-mL whole
blood was lysed in 1.8 mL of the denaturing
solution using a glass homogenizer.  The lysate
was collected in a new 15-mL tube, and added
with 1/10 volume of 2-mol/L sodium acetate,
pH 4.0, an equal volume of water-saturated
phenol and 1/2 volume of chloroform and
isoamylalcohol mixture (24:1).  After incuba-
tion for 15 min on ice, the mixture was centri-
fuged at 3000 rpm for 40 min at 4˚C.  The su-
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Table 1.  Nucleotide sequence of primers
Pair Polarity Name Sequence (5'–3') Base position
Outer Antisense BD980 CATTGTGGGGTTTTCCTTCTTACTC 1004 – 980
Sense BD579 CCATCCCATGGTGAGACTGCTACAC   579 – 603
Inner Antisense BD908 CTTGATAGCGTCGGGGTGTCTAATG   932 – 908
Sense BD653 ACCCTGGGTAGGCTCCTTTGTGTTG   653 – 677
pernatant RNA was precipitated with an equal
volume of 2-propanol at –20˚C.  After centri-
fugation in the same conditions, the RNA was
dissolved in 300 µL of the denaturing solution,
and precipitated by the 2-propanol.  Following
centrifugation at 15,000 rpm for 15 min at 4˚C,
the RNA pellet was washed by 70% ethanol and
vacuum dried.  Finally, the pellet was dissolved
in 50 µL of water and preserved at –80˚C for
further use.  All the equipment and water used
in the study were treated with 0.01% diethyl-
pyrocarbonate and autoclaved.
Primers
Primers were designed to amplify the conserved
region coded by the BDV p40 gene based on pub-
lished sequences (GeneBank: BDU04608 and
BDU94867).  Customized oligonucleotide prim-
ers (Table 1) were purchased from Pharmacia
Biotech (Tokyo, Japan).
Analysis of BDV RNA by nested RT-PCR
The reaction mixture of reverse transcription in
a volume of 10 µL contained 50-mmol/L Tris-
HCl, pH 8.3, 75-mmol/L KCl, 3-mmol/L MgCl2,
1 µL of the RNA stock (equivalent to the nu-
cleated cells in 20 µL of blood), 2-mmol/L
dithiothreitol, 0.5 mmol/L each dNTP (Takara
Shuzo, Kyoto, Japan), 5-µmol/L of the sense
primer BD579, 200 U of Superscript II reverse
transcriptase (Gibco BRL, Gaithersburg, MD)
and 1 U of RNasinA (Promega, Madison, WI).
After incubation at 45˚C for 60 min, the whole
reaction mixture was served to the following
PCR.
The cDNA was amplified in a program-
mable incubator (API300, ASTEC, Fukuoka,
Japan) for 35 cycles.  The 50-µL reaction mix-
ture contained the cDNA, 20-mmol/L Tris-HCl,
pH 8.5, 50-mmol/L KCl, 1.5-mmol/L MgCl2,
0.2 mmol/L each dNTP, 0.5-µmol/L the outer
primer pair (BD980 and BD579) and 1.25 U of
Taq DNA polymerase (Pharmacia Biotech,
Uppsala, Sweden).  Each cycle consisted of 1
min at 94˚C (2 min on the first cycle), 1 min at
52˚C and 1 min at 72˚C (10 min on the final
cycle).  A 5-µL aliquot of the first PCR product
was served to the second PCR with the inner
primer pair (BD908 and BD653) for another 35
cycles.  A 7-µL portion of the nested PCR prod-
uct was electrophoresed on a composite gel
containing 2% NuSieve GTG agarose (FMC
Bioproducts, Rockland, ME) and 1% LO3 agar-
ose (Takara Shuzo), and stained with ethidium
bromide.  To avoid possible contamination,
separate rooms served as sites for RNA extrac-
tion, PCR reaction and gel electrophoresis.
Results
BDV seroprevalence in normal Bangla-
deshi horses
Out of 48 normal horses tested for the BDV
antibody by the ECLIA method, 11 (23%) were
positive (Table 2).  Although 5 additional
horses (identification number 5, 11, 21, 29 and
35) showed an ECLIA titer of > 1000 in the
anti-(rp24 + rp40) assay, they did not show a
significant reduction in ECLIA count compared
to the competing antigen.  None of these
showed a significant reaction in either the anti-
rp24 or anti-rp40 assay.  Therefore, we judged
the reactions in the anti-(rp24 + rp40) assay as
false.  All of the positive sera were positive only
for anti-p24, but not significantly for anti-p40
of BDV.
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Table 2.  Seroprevalence of BDV in normal horses in Bangladesh
  ID No.* Sex Age Anti-(rp24 + rp40) Anti-rp24 Anti-rp40 Judgment
(year) ECLIA % Inhibition† ECLIA ECLIA
3 m 0.1 68 0 0 0 –
39 m 0.1 372 0 0 0 –
41 m 0.1 652 0 0 0 –
47 m 0.1 754 0 0 0 –
37 f 0.8 73 0 0 0 –
2 m 1.0 159 0 0 0 –
27 m 1.0 59 0 0 0 –
21 f 1.1 1144 33 0 0 –
28 m 1.1 2583 64 3456 395 Anti-p24
14 m 1.2 309 0 0 0 –
18 m 1.2 1922 78 2674 244 Anti-p24
22 f 1.2 111 0 0 0 –
31 m 1.2 160 0 0 0 –
33 m 1.2 1820 84 2587 283 Anti-p24
42 m 1.2 266 0 0 0 –
48 m 1.2 967 0 0 0 –
5 m 1.3 1749 0 0 0 –
35 m 1.3 1818 10 0 0 –
43 m 1.3 1776 74 2996 257 Anti-p24
8 f 1.4 167 0 0 0 –
15 m 1.4 695 0 0 0 –
32 m 1.4 224 0 0 0 –
4 m 1.5 1790 87 2445 299 Anti-p24
13 f 1.6 261 0 0 0 –
45 f 1.6 1742 74 2554 243 Anti-p24
6 m 1.8 206 0 0 0 –
19 m 1.8 211 0 0 0 –
38 m 1.8 3597 97 5388 68 Anti-p24
20 m 2.0 773 0 0 0 –
26 m 2.0 245 0 0 0 –
46 f 2.0 133 0 0 0 –
24 f 2.2 937 0 0 0 –
25 m 3.0 739 0 0 0 –
30 m 3.0 273 0 0 0 –
1 m 3.2 3572 96 5483 72 Anti-p24
9 m 5.0 127 0 0 0 –
36 m 6.0 54 0 0 0 –
17 m 6.2 325 0 0 0 –
10 m 8.0 2752 87 3813 395 Anti-p24
16 m 8.0 217 0 0 0 –
29 m 8.0 1617 11 0 0 –
40 m 8.0 201 0 0 0 –
44 f 8.0 196 0 0 0 –
7 f 10.0 6757 97 10420 129 Anti-p24
11 f 10.0 1488 0 0 0 –
12 f 10.0 258 0 0 0 –
23 m 11.0 460 0 0 0 –
34 f 11.0 6839 97 10352 156 Anti-p24
–, negative; BDV, Borna disease virus; ECLIA, electrochemiluminescence immunoassay; f, female; m,
male.
* Identification number of the horses.
† % Inhibition of ECLIA counts by purified competing antigen.  Samples with ≥ 50% inhibition were
considered as specific for BDV.
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Table 4.  ECLIA titer of anti-BDV antibody-positive horses
Age group ECLIA titer P*
 (year) Geometric average 95% Confidence interval
1 3041 2192 –  4121 0.012
≥ 3 6887 3126 –15171
BDV, Borna disease virus; ECLIA, electrochemiluminescence immunoassay.
* Mann-Whitney test.
Table 3.  Age-based distribution of total and anti-BDV antibody-positive horses
Age group Total of tested horses Anti-BDV antibody-positive horses
 (year) Number Male/female ratio Number Male/female ratio Percentage
< 1 5   4:1 0 0:0 0
1 23 18:5 7 6:1 30
2 4   2:2 0 0:0 0
≥ 3 16 11:5 4 2:2 25
BDV, Borna disease virus.
None of the 5 horses at the age of < 1 year
was positive (Table 3).  However, 7 of 23 horses
(30%) at the age of 1 year were positive, as well
as 4 of 16 horses (25%) at the ages of ≥ 3 years.
Although the positive rate was not significantly
higher in the older age group, the geometric
average of the ECLIA titer of the antibody-
positive horses at the age of 1 year was signifi-
cantly lower than those at the ages of ≥ 3 years
by the Mann-Whitney test (P = 0.012) (Table
4).  With this small sized sample, sexual prefer-
ence in the prevalence of anti-BDV was not
evident.
BDV antibody in the horses caretakers
The 26 horse caretakers were tested for anti-
BDV antibody.  All the individuals were male
with an age range of 12 to 54 years who have
been taking care of the horses under the same
roof.  None of them was positive including
those who were taking care of the antibody-
positive horses (Table 5).  Although 2 care-
takers (identification number 6 and 25) had a
ECLIA titer of > 1000 in the anti-(rp24 + rp40)
assay, they were considered negative because
their reactivity showed no significant competi-
tion from preincubation with the purified rp24
and rp40.
BDV-RNA in the horse blood
To check the presence of BDV in the blood,
total RNA extracted from the nucleated cell
fraction in the blood was tested in the RT-PCR
directed toward the p40 region of BDV.  The
sensitivity of the RT-PCR was 200 molecules of
in vitro synthesized BDV p40 RNA per reaction
(Fig. 1A). None of the 11 seropositive horses
(Fig. 1B) and none of 5 randomly selected
seronegative horses (data not shown) gave any
positive signal for BDV RNA by RT-PCR.
Both of the 2 positive control tubes containing a
double amount of threshold level BDV RNA
(Fig. 1B, Lanes P) showed a clear positive sig-
nal at the expected 280 nt length.
Discussion
Eleven (23%) of 48 healthy domestic Bangladeshi
horses were found positive for anti-BDV by
ECLIA.  Since there is no report on the preva-
lence of BDV in horses in southeast Asia, this
report has expanded the area of BDV infiltration
in the world.  Overall prevalence was similar to
that reported in other countries, such as Japan,
Iran, Germany and Sweden, although the test
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Fig. 1.  Nested reverse transcription-polymerase chain reaction (RT-PCR) for Borna disease virus (BDV).
Nested PCR products were electrophoresed in a composite gel containing 2% NuSieve GTG agarose and 1%
LO3 agarose and stained with ethidium bromide.  The expected size of the product was 280 nucleotides.  A:
Sensitivity of the nested RT-PCR.  Lane M:  φX174 HaeIII digest.  Lanes 1 to 5:  800, 400, 200, 100 and 50
copies of in vitro transcribed BDV RNA/reaction, respectively.  B:  The nested RT-PCR of the horse blood.
Lane M:  φX174 HaeIII digest.  Lane N:  template-free control.  Lane P:  400 copies of the in vitro transcribed
BDV RNA (the double amount of the threshold shown in A-Lane 3).  Lanes 1 to 11:  total RNA extracted from
nucleated cells in 20-µL equivalent of whole blood of the 11 BDV antibody-positive horse blood specimens
(horse identification number 1, 4, 7, 10, 18, 28, 33, 34, 38, 43 and 45, respectively).  bp, base pair.
Table 5.  Seroprevalence of anti-BDV antibody among horse caretakers in Bangladesh
ID No.* Sex Age Anti-(rp24+rp40) Anti-rp24 Anti-rp40 Judgment
(year) ECLIA % Inhibition† ECLIA ECLIA
4 m 12 199 0 0 0 –
12 m 12 73 0 0 0 –
3 m 16 48 0 0 0 –
10 m 16 462 0 0 0 –
1 m 18 6 0 0 0 –
6 m 18 1493 2 0 0 –
9 m 18 56 0 0 0 –
11 m 18 152 0 0 0 –
19 m 18 97 0 0 0 –
25 m 18 1204 0 0 0 –
18 m 19 116 0 0 0 –
26 m 19 15 0 0 0 –
5 m 20 79 0 0 0 –
13 m 20 114 0 0 0 –
17 m 20 20 0 0 0 –
7 m 21 33 0 0 0 –
16 m 21 225 0 0 0 –
2 m 22 5 0 0 0 –
8 m 22 30 0 0 0 –
14 m 22 36 0 0 0 –
15 m 22 39 0 0 0 –
24 m 22 65 0 0 0 –
20 m 23 468 0 0 0 –
21 m 32 124 0 0 0 –
23 m 32 72 0 0 0 –
22 m 54 69 0 0 0 –
–, negative; BVD, Borna disease virus; ECLIA, electrochemiluminescence immunoassay; m, male.
* Identification number of the horse caretakers.
† % Inhibition of ECLIA counts by purified competing antigen.  Samples with ≥ 50% inhibition were
considered as specific for BDV.
M 1 2 3 4 5
M N P P 1 2 3 4 5 6 7 8 9 10 11 B
280 bp
A
280 bp
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method is not uniform (Table 6).  A recent
report by ECLIA on Japanese feral horses
(Yamaguchi et al., 1999) was also consistent
with this research.  In contrast, the prevalence
reported in the United States and Austria was
significantly lower than these reports (Kao et al.,
1993; Weissenbock et al., 1998).  This may
suggest that the penetration of BDV in horses
may not be homogeneous in the world.  Alterna-
tively, the difference may depend on methodol-
ogy, since the technology of anti-BDV antibody
assay systems is still controversial.  Every assay
system has a non-specific reactivity.  The anti-
body titer against p40, the major internal pro-
tein of BDV, is not always predominant in vari-
ous host species (Yamaguchi et al., 1999), al-
though the major internal protein is the pre-
dominant target of antibodies in most virus-host
interactions.  Development of a durable anti-
body assay system for the envelope protein of
BDV may solve the problem.
Studies on horses in the United States and
Iran done with the Western blotting described
the predominant reactivity in the anti-p40 anti-
body (Table 6) (Kao et al., 1993; Bahmani et
al., 1996).  Two other independent reports from
Japan (Nakamura et al., 1995; Yamaguchi et al.,
1999) and this report found that most seroposi-
tive horses were only positive for anti-p24 anti-
body, but not for anti-p40 antibody by Western
blotting and/or ECLIA.  Since the BDV infec-
Table 6.  Geographical prevalence of BDV among the normal horse population
Country Method Anti-(p24 + p40) Anti-p24 Anti-p40    RNA in PBMCs Reference
Ratio† Positivity Positivity* Positivity* Ratio† Positivity   number
(%) (%) (%) (%)
United States WB 18/295   6.1 NR 100    NR 10
Japan WB 15/ 57 26.3 100  NR 17/57 30 16
Iran WB 13/ 72 18.0 85 100 17/72 24 1
Germany IF 29/100 29.0 NR  NR    NR 18
Austria IF  2/100 2.0 NR  NR    NR 26
Sweden ELISA 13/ 53 24.5 NR  NR   1/53 2 4
Japan ECLIA 16/ 89 18.0 100   13    NR 27
Bangladesh ECLIA 11/ 48 23.0 100     0   0/11 0 This study
BDV, Borna disease virus; ECLIA, electrochemiluminescence immunoassay; ELISA, enzyme-linked
immunosorbent assay; IF, indirect immnofluorescence; NR, not reported; PBMC, peripheral blood mono-
nuclear cell; WB, Western blotting.
* Of samples with anti-(p24 + p40) antibody.
† Number of positive horses/number of tested horses.
tion is cell-associated and notoriously dormant
(Ludwig et al., 1973), the replication status or
genetic background in each horse may result in
this phenotypic difference.  As far as we know,
all the sequence data available on horse BDV
are only from Germany (Bode and Ludwig,
1997).  The p40 antigenic determinants of BDV
in different areas of the world may be hetero-
geneous.  If that is the case, since the ECLIA
system used a cloned rp40 antigen derived from
the Madian-Darby canine kidney/BDV cell line
chronically infected with German horse BDV,
anti-(Asian p40) in the Bangladeshi horse may
not be as reactive as German anti-p40.  Isolation
of a BDV of Asian origin may solve the prob-
lem.
All of the 5 horses below the age of 1 year
were negative, and the difference in antibody
titer in the age of 1 year and ≥ 3 years was sta-
tistically insignificant.  The result suggests that
BDV is spreading horizontally in the younger
horses.  However, we do not have an explana-
tion of how the virus spreads.
Transmission of BDV from horses to hu-
mans has been suggested by a higher preva-
lence of BDV in blood donors near a horse farm
(Takahashi et al., 1997).  Contradictory to these
reports, we could not find any BDV-seroposi-
tive caretakers in our study in spite of the fact
that all of them were living under the same roof
with highly prevalent horses.  Therefore, we
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could not find any evidence to suggest BDV
transmission from horses to humans.
Recently Nakamura et al. (1995) detected
the BDV RNA in normal healthy horses in
Japan, and Berg et al. (1999) in horses with be-
havior disorders in Sweden.  We failed to prove
that BDV RNA in seropositive horses was con-
sistent with the results of Richt et al. (1997).
Most of the studies which have tried to detect
the BDV genome in human samples have used
peripheral blood mononuclear cells.  Bode et al.
(1995) claimed that they detected the BDV
RNA in the blood of psychiatric patients.  On
the other hand, Richt et al. (1997) failed to de-
tect BDV RNA in psychiatric patients and
argued that the most positive signals in the RT-
PCR were due to laboratory contamination.
They stated that their laboratory had no prior
exposure to BDV experimentation.  The ab-
sence of BDV-specific RNA sequences in the
cellular fraction of the blood in our results does
not exclude the possibility that BDV stays in the
restricted areas of the brain as in the cases of
naturally and experimentally infected animals
(Rott and Becht, 1995).
This is the first report of the presence of
BDV in horses in a southeast Asian country,
Bangladesh.  We failed to detect BDV RNA in
horse blood, nor could we obtain evidence
which suggests the zoonotic spread of BDV
from infected horses to closely associated care-
takers.
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